Cholinergic pathway

The cholinergic pathway is a fundamental neurotransmitter system utilizing acetylcholine (ACh) to transmit signals across the central and peripheral nervous systems [StatPearls: Physiology, Acetylcholine]. In the brain, cholinergic projections from the basal forebrain are critical for executive function, memory, and attention, while in the periphery, the pathway governs the parasympathetic nervous system and the neuromuscular junction [PubMed: PMID 29051558]. The pathway's molecular machinery includes the synthetic enzyme choline acetyltransferase (ChAT), the degradative enzyme acetylcholinesterase (AChE), and two main classes of receptors: nicotinic (ionotropic) and muscarinic (metabotropic) receptors [UniProt: P06276, P22303]. Dysfunction in cholinergic signaling is a primary feature of Alzheimer's disease, leading to the 'cholinergic hypothesis' which drove the development of current standard-of-care treatments [NIH: Alzheimer's Disease Fact Sheet]. Therapeutic strategies typically involve inhibiting AChE to prolong the action of endogenous ACh or using specific receptor agonists and antagonists to treat conditions ranging from glaucoma to overactive bladder and cognitive impairment [PubChem: Donepezil]. Because this entry describes an entire biological system rather than a single molecular entity, it is classified as 'incorrect' for specific target mapping.

Other names

Cholinergic systemAcetylcholine signaling pathwayACh pathway

Drugs targeting this pathway act by inhibiting the enzyme acetylcholinesterase to prevent the breakdown of acetylcholine, thereby increasing its concentration in the synaptic cleft, or by acting as agonists or antagonists at muscarinic and nicotinic receptors to modulate autonomic and central nervous system activity [StatPearls: Acetylcholinesterase Inhibitors].